Hiroshi Nishioka

Hiroshi Nishioka

Auto-generated profile, based on publicly available information

Hiroshi Nishioka

Department of Plastic and Reconstructive Surgery, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2013 in Cephalalgia
Verified
Journal Article
Closed access
MFMitsue Fujita
Mitsue Fujita
KSKatsuaki Sato
Katsuaki Sato
HNHiroshi Nishioka
Hiroshi Nishioka
FSFumihiko Sakai
Fumihiko Sakai
Objective: The objective of this article is to evaluate the efficacy and tolerability of two doses of oral sumatriptan vs placebo in the acute treatment of migraine in children and adolescents. Background: Currently, there is no approved prescription medication in Japan for the treatment of migraine in children and adolescents. Methods: This was a multicenter, outpatient, single-attack, double-blind, randomized, placebo-controlled, parallel-group study. Eligible patients were children and adolescents aged 10 to 17 years diagnosed with migraine with or without aura (ICHD-II criteria 1.1 or 1.2) from 17 centers. They were randomized to receive sumatriptan 25 mg, 50 mg or placebo (1:1:2). The primary efficacy endpoint was headache relief by two grades on a five-grade scale at two hours post-dose. Results: A total of 178 patients from 17 centers in Japan were enrolled and randomized to an investigational product in double-blind fashion. Of these, 144 patients self-treated a single migraine attack, and all provided a post-dose efficacy assessment and completed the study. The percentage of patients in the full analysis set (FAS) population who report pain relief at two hours post-treatment for the primary endpoint was higher in the placebo group than in the pooled sumatriptan group (38.6% vs 31.1%, 95% CI: −23.02 to 8.04, p = 0.345). The percentage of patients in the FAS population who reported pain relief at four hours post-dose was higher in the pooled sumatriptan group (63.5%) than in the placebo group (51.4%) but failed to achieve statistical significance ( p = 0.142). At four hours post-dose, percentages of patients who were pain free or had complete relief of photophobia or phonophobia were numerically higher in the sumatriptan pooled group compared to placebo. Both doses of oral sumatriptan were well tolerated. No adverse events (AEs) were serious or led to study withdrawal. The most common AEs were somnolence in 6% (two patients) in the sumatriptan 25 mg treatment group and chest discomfort in 7% (three patients) in the sumatriptan 50 mg treatment group. Conclusions: There was no statistically significant improvement between the sumatriptan pooled group and the placebo group for pain relief at two hours. Oral sumatriptan was well tolerated.

1 January 2018 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
HNHiroshi Nishioka
Hiroshi Nishioka
SKShoji Kondoh
Shoji Kondoh
SYShunsuke Yuzuriha
Shunsuke Yuzuriha

1 August 2018 in Medicine
Verified
Journal Article
Closed access
YNYuta Nakajima
Yuta Nakajima
SKShoji Kondoh
Shoji Kondoh
HNHiroshi Nishioka
Hiroshi Nishioka
WKWataru Kasuga
Wataru Kasuga
Several operative techniques for inframammary fold (IMF) reconstruction have been described and have resolved the shortcomings of conventional methods. However, there are still difficulties with IMF reconstruction, that is, performance through small mastectomy scars, creation of a smooth IMF curve, transfer of external IMF markings to the interior chest wall, or determining correct IMF without an implant in place. We have used a type of anchor suture with a completely percutaneous approach, the vertical pendulum suture (VP suture), to reconstruct the IMF easily in implant-based breast reconstruction. The VP suture requires a pair of skin incisions a few millimeters in length (incisions A and B). The needle passes through the subcutaneous tissue from incision A, the chest wall, again through the subcutaneous tissue, and exits from incision B. Then, the needle passes through the edge of the dermis from incision B, the superficial layer of the subcutaneous tissue, again through the other edge of the dermis, and exits from incision A. The knot is tied and buried in the subcutaneous tissue. The whole technique can be performed percutaneously without visualizing the inside of the pocket. A retrospective case series study of photographs and chart review was conducted for all cases of unilateral implant-based breast reconstruction performed from December 2016 to December 2017 at Ina Central Hospital, Ina, Japan. Nine consecutive patients underwent unilateral implant-based breast reconstruction. Five patients treated using the VP suture were included in this study. All 5 patients showed good esthetic results over the follow-up period (average, 11 months). Scalloped appearance was observed in all patients, but flattened spontaneously and disappeared within 3 months postoperatively. There were no complications, such as hematoma, infection, skin necrosis, pneumothorax, seroma, scar contracture, or implant injury. The VP suture is completely percutaneous, parallel to the IMF, and is easy to perform at any time during surgery regardless of whether the implant is in place or not. IMF reconstruction is facilitated by freeing the surgeon from the need to visualize the inside of the pocket.

31 January 2024 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
PDF file
YIYoshikazu Inoue
Yoshikazu Inoue
HNHiroshi Nishioka
Hiroshi Nishioka
MIMaki Inukai
Maki Inukai
YSYusuke Shimizu
Yusuke Shimizu
MKMasato Kimura
Masato Kimura
TOTakayuki Okumoto
Takayuki Okumoto
Background: Laser hair removal (LHR) is one of the most requested cosmetic procedures worldwide. A rare side effect is the appearance of excess hair around previously treated areas, known as paradoxical hypertrichosis. Objectives: The aim of this study was to retrospectively identify the cause of this side effect. Methods: This study included all patients who underwent LHR at our center between November 2018 and November 2020. Alexandrite laser hair removal (HR) or diode laser super hair removal (SHR) was performed in 70% and 30% of cases, respectively. Clinical features and daily habits of patients with and without postlaser hypertrichosis were compared. Results: Of the 7381 patients who received LHR, 25 patients (0.34%) demonstrated an increase in hair growth compared to baseline. Of these 25 patients, 24 had been treated with alexandrite laser HR (P < .01). The most common site was the upper arm, followed by the periareolar area. Daily sun protection was associated with a significantly lower incidence of hypertrichosis (P < .05), as was confirmed and shown to be independent of Fitzpatrick skin type by binary logistic regression analysis (odds ratio = 0.41, P < .05). Conclusions: In our clinic, we observed paradoxical hypertrichosis after laser hair removal in a small minority of cases, as described by others. We did not observe differences in incidence related to skin type, but daily sun protection and LHR with diode laser SHR were associated with significant reductions in incidence rates. In addition to previously reported common sites, we also identified the periareolar area as a high-risk region.

2 May 2022 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
HNHiroshi Nishioka
Hiroshi Nishioka
SYShunsuke Yuzuriha
Shunsuke Yuzuriha
DYDaisuke Yanagisawa
Daisuke Yanagisawa

30 September 2024 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
HNHiroshi Nishioka
Hiroshi Nishioka
ITIkkei Takashimizu
Ikkei Takashimizu
SYShunsuke Yuzuriha
Shunsuke Yuzuriha